ClinicalTrials.gg
CompletedNCT00820664Updated Jan 22, 2016Results posted

A Clinical Study to Evaluate the Effects of Estrogen in Healthy Postmenopausal Women

A Phase 1 interventional study of Comparator: Estrace 0.5 mg and Comparator: Estrace 2 mg in Postmenopausal Symptoms, sponsored by Merck Sharp & Dohme LLC. Completed. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-22.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

The purpose of this study is to examine the effect of two different dose levels of estrogen or placebo in healthy postmenopausal women by measuring the changes in hormone levels and examining the changes in the uterine lining (endometrium).

02

Conditions studied

  • Postmenopausal Symptoms
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is a healthy woman less than or equal to 65 years of age with onset of menopause less than or equal to 10 years prior to prestudy visit 1
  • Patient has a uterus and no history of uterine bleeding in the past 3 months
  • Patient has not had a previous endometrial within the last 4 weeks
  • Patient has had a normal mammogram within the last 11 months
  • Patient has had a normal pap-smear within the past 3 years prior to screening
  • Patient has had a normal transvaginal ultrasound of the endometrium
  • Patient is willing to avoid strenuous physical activity such as strenuous or unaccustomed weight lifting, running, bicycling, etc for the duration of the study
  • Patient agrees to not consume grapefruit products beginning approximately 2 weeks prior to the first dose of study drug and throughout the study
  • Patient agrees to limit daily consumption of alcohol. During the study, daily alcohol consumption should not be more than 2 glasses
  • Patient agrees to limit daily consumption of caffeine. During the study, daily caffeine consumption should not exceed 3 cups of coffee
  • Patient is a non-smoker

Exclusion criteria

Exclusion Criteria:

  • Patient is mentally or legally incapacitated
  • Patient has a history of any first degree relatives with breast or endometrial cancer
  • Patient has a history of multiple and/or severe allergies to prescription or non-prescription drugs or food
  • Patient has used any type of estrogen or progesterone preparation unless followed by appropriate
  • Patient has had surgery, donated approximately 500 mL of blood or has participated in another study within the last 4 weeks
  • Patient has a history of deep vein thromboses, coronary artery disease, heart attack or stroke
  • Patient is a current user of illegal drugs
  • Patient has a history of to estrogen products
  • Patient is unable to refrain from using anti-coagulants
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
29 participants (actual)

Study arms

  • Active comparator
    17β-estradiol 2.0 milligrams

    Estrace 2.0 mg tablet

    Drug: Comparator: Estrace 2 mg

  • Active comparator
    17β-estradiol 0.5 milligrams

    Estrace 0.5 mg tablet

    Drug: Comparator: Estrace 0.5 mg

  • Placebo comparator
    3

    Placebo

    Drug: Comparator: Placebo

Interventions

  • 0.5 mg tablet taken once daily for 28 days

    Also known as: Estrace

  • 2 mg tablets taken once daily for 28 days.

    Also known as: Estrace

  • DrugComparator: Placebo

    Placebo 0 mg capsule taken once daily for 28 days

06

What researchers measure

Primary outcomes

  1. Immunohistochemistry (IHC) Proliferative Effects Measurement

    Ratio of the total number of positively stained cell nuclei to the total number of cell nuclei. Proliferating endometrial cells express the Ki-67 antigen. The ratio was converted to a percent proliferating cells by taking the number of Ki-67 positive stained nuclei in a given field and dividing by the total number of nuclei in that field and multiplying by 100. At least 5 high power fields were scored in this manner and an aggregate percent Ki-67 positive cells was reported. Square root transformation was taken to make it approximately normally distributed for an ANOVA model to apply.

    Time frame: 4 weeks

Secondary outcomes

  1. Mean Gene Expression Intensity After 4 Weeks of Either 0.5 or 2 mg Estrace Compared to Placebo.

    Time frame: 4 weeks

07

Results

Posted May 7, 2010
Limitations and caveats
The registered secondary outcome: "Mean gene expression intensity after 4 weeks of either 0.5 or 2 mg Estrace compared to placebo" results are not available because of inadequate quantity and quality of tissue samples that were obtained.

Participant flow

Patients were recruited through advertisement and review of patient databases at Comprehensive Phase I, USA, between December 2008 and April 2009.

Participant flow — Overall Study
Milestone17β-estradiol 2.0 Milligrams17β-estradiol 0.5 MilligramsPlacebo
Started9119
Completed9119
Not completed000

Outcome measures

PrimaryImmunohistochemistry (IHC) Proliferative Effects Measurement

Ratio of the total number of positively stained cell nuclei to the total number of cell nuclei. Proliferating endometrial cells express the Ki-67 antigen. The ratio was converted to a percent proliferating cells by taking the number of Ki-67 positive stained nuclei in a given field and dividing by the total number of nuclei in that field and multiplying by 100. At least 5 high power fields were scored in this manner and an aggregate percent Ki-67 positive cells was reported. Square root transformation was taken to make it approximately normally distributed for an ANOVA model to apply.

Time frame:
4 weeks
Reported as:
Least squares mean · Square root of % positive stained cells
Immunohistochemistry (IHC) Proliferative Effects Measurement
Square root of % positive stained cells17β-estradiol 2.0 Milligrams17β-estradiol 0.5 MilligramsPlacebo
Immunohistochemistry (IHC) Proliferative Effects Measurement0.73 (0.61 to 0.86)0.43 (0.32 to 0.54)0.25 (0.12 to 0.37)
Statistical analysis
  • 17β-estradiol 2.0 Milligrams vs Placebo · ANOVA · p = <0.001 (1-sided, alpha=0.05) · Least squares mean: 0.49 · 95% CI 0.31 to 1.00A one-way ANOVA model with term treatment was fit to the square root transformed response.
  • 17β-estradiol 0.5 Milligrams vs Placebo · ANOVA · p = 0.032 (1-sided, alpha=0.05) · Least squares mean: 0.19 · 95% CI 0.02 to 1.00A one-way ANOVA model with term treatment was fit to the square root transformed response.
SecondaryMean Gene Expression Intensity After 4 Weeks of Either 0.5 or 2 mg Estrace Compared to Placebo.
Time frame:
4 weeks

Results for this outcome have not been posted.

Adverse events

Collected over Reported AE data were collected during the period of the study from date of informed consent to the 14 day follow up period following completion of treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
17β-estradiol 2.0 Milligrams—0/9 (0%)7/9 (77.8%)
17β-estradiol 0.5 Milligrams—0/11 (0%)6/11 (54.5%)
Placebo—0/9 (0%)6/9 (66.7%)
Most frequent other events
Showing 10 of 30
Most frequent other events
Event17β-estradiol 2.0 Milligrams17β-estradiol 0.5 MilligramsPlacebo
Vaginal HaemorrhageReproductive system and breast disorders4/91/110/9
CoughRespiratory, thoracic and mediastinal disorders0/90/113/9
Abdominal DiscomfortGastrointestinal disorders2/90/110/9
Abdominal PainGastrointestinal disorders2/92/112/9
Blood Pressure IncreasedInvestigations0/90/112/9
HeadacheNervous system disorders2/91/111/9
Vulvovaginal PruritusReproductive system and breast disorders2/90/110/9
Back PainMusculoskeletal and connective tissue disorders0/92/110/9
DizzinessNervous system disorders1/92/111/9
Vision BlurredEye disorders1/90/110/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)17β-estradiol 2.0 Milligrams17β-estradiol 0.5 MilligramsPlaceboTotal
Mean54.11 ± 3.7653.91 ± 5.6555.33 ± 3.0454.41 ± 4.30
Sex: Female, Male
Sex: Female, Male(Participants)17β-estradiol 2.0 Milligrams17β-estradiol 0.5 MilligramsPlaceboTotal
Female911929
Male0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)17β-estradiol 2.0 Milligrams17β-estradiol 0.5 MilligramsPlaceboTotal
Black1001
White811928
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)17β-estradiol 2.0 Milligrams17β-estradiol 0.5 MilligramsPlaceboTotal
Mean27.87 ± 3.9528.69 ± 2.7427.43 ± 1.9828.05 ± 2.92
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2010, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2009
First posted
Jan 12, 2009
Start
Dec 2008
Primary completionActual
May 2009
CompletionActual
May 2009
Results first posted
May 7, 2010
Last update
Jan 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00820664
Responsible party
Sponsor
First posted
Jan 12, 2009
Start date
Dec 2008
Primary completion
May 2009
Completion
May 2009
Results posted
May 7, 2010
Last update
Jan 22, 2016

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion